Evotec SE (NASDAQ:EVO) Short Interest Update

Evotec SE (NASDAQ:EVO) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 766,200 shares, an increase of 89.9% from the December 15th total of 403,500 shares. Based on an average daily volume of 232,100 shares, the short-interest ratio is currently 3.3 days. Currently, 0.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC purchased a new position in Evotec during the 2nd quarter worth $87,000. DCF Advisers LLC boosted its holdings in Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after acquiring an additional 67,156 shares in the last quarter. Novo Holdings A S acquired a new stake in Evotec in the second quarter worth about $71,183,000. Mediolanum International Funds Ltd purchased a new stake in shares of Evotec during the third quarter worth about $512,000. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of Evotec during the third quarter valued at about $104,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Stock Down 2.4 %

EVO stock traded down $0.10 during trading on Tuesday, reaching $4.08. 49,513 shares of the company traded hands, compared to its average volume of 59,552. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The business has a 50 day simple moving average of $4.63 and a 200 day simple moving average of $4.12. Evotec has a 12 month low of $2.85 and a 12 month high of $8.39.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Evotec in a report on Thursday, November 7th. Jefferies Financial Group downgraded shares of Evotec from a “buy” rating to a “hold” rating and dropped their price objective for the company from $8.70 to $3.80 in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.93.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.